

Stock Sentiment Analysis Report

Pacific Biosciences (PACB)

Analysis Period: 2026-03-22 to 2026-04-21 (30 days)

Generated: 2026-04-21 10:04:21

Executive Summary


Sentiment analysis for Pacific Biosciences (PACB) from 2026-03-22 to 2026-04-21. Analyzed 68 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	21	30.9%
Negative	16	23.5%
Neutral	31	45.6%
Total	68	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
PacBio Secures Agreement with Basecamp Research fo...	alpha_vantage	2026-03-27	0.670
Oncology Precision Medicine Market Trends and Inve...	news	2026-03-27	0.637
Reduced legacy precipitation decreases microbial c...	pubmed	2026 Apr 1	0.625
Pacific Biosciences stock (US6932471010): Is long-...	alpha_vantage	2026-04-18	0.511
Scaling genomic reanalysis to unlock diagnoses and...	pubmed	2026 Apr 9	0.494

Top Negative Events

Title	Source	Date	Score
Genomic analysis of human-infecting Leptospira bor...	news	2026-03-27	-0.791
Pacific Biosciences of California unveils SPRQ-Nx ...	alpha_vantage	2026-04-09	-0.660
Powering cancer testing research with HiFi whole g...	alpha_vantage	2026-04-02	-0.660
Pacific Biosciences of California (PACB) Suffers a...	alpha_vantage	2026-04-14	-0.637
Pacific Biosciences of California (PACB) Reports Q...	alpha_vantage	2026-03-28	-0.518